Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, said the move was a "win win" saying: We now have medicines that not only reduce heart attacks, strokes, and peripheral arterial disease, but also simultaneously lead to meaningful weight loss which in turn lowers the risk of many weight-related conditions
Clinical trials and real-world data consistently show significant weight loss from treatment with Ozempic, Semaglutide and Tirzepatide: Unfortunately, weight regain is a well-documented phenomenon after discontinuation of treatment: SURMOUNT 4 trial- Weight regain after stopping Tirzepatide after 36 weeks versus continuation of treatment Beyond weight regain, the discontinuation of GLP-1 agonists may reverse cardiometabolic benefits: Ongoing trials (e.g., SELECT and SURPASS-CVOT) aim to clarify whether continued use is necessary for sustained cardiovascular risk reduction
Pfizer provides update on oral GLP-1 receptor agonist danuglipron [press release]
Evening injection is recommended because nausea and flushing peak 30-90 minutes after injection, and sleeping through the side effects is the simplest management strategy
